QLS1304 plus hormone therapy for ER+ breast cancer
Part of Cancer clinical trials.
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic breast cancer that is ER-positive and HER2-negative.
- You have already tried at least one type of hormone therapy and it stopped working.
- You are 18 years or older and are generally able to take care of yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans (like CT or MRI).
- You have not had any other active cancer in the last 3 years (except some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.
Hear when a new Advanced ER+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.